Indian Generics Gain Ground in China as the Global Procurement Landscape Demands a New Industrial Model

Indian pharmaceutical manufacturers expanded their position in China’s tightly regulated drug market this year, securing several high-volume supply contracts under the country’s volume-based procurement (VBP) program. Hetero Labs, Cipla, Annora Pharma, and Natco Pharma won bids for seven products—including the high-demand diabetes therapy dapagliflozin—according to the India–China Economic and Cultural Council (ICEC). These wins affirm India’s long-standing cost competitiveness but also underscore a structural shift: global procurement systems no longer accept the operational standards that built the first generation of Indian generics leadership.

Indian Firms Make New Inroads in China’s Diabetes and Chronic-Disease Market

Indian pharma firms operating in China have made notable progress in penetrating the Chinese generics market, particularly through wins for bulk generic drugs such as dapagliflozin, one of the most widely prescribed therapies for type 2 diabetes worldwide. Dapagliflozin’s inclusion is significant: China has more than 140 million people with diabetes, the largest diabetic population globally, and demand for SGLT2 inhibitors continues to rise as treatment guidelines shift toward cardiometabolic protection.

Securing dapagliflozin contracts positions Indian companies at the center of one of China’s fastest-growing therapeutic categories—diabetes and chronic metabolic disease—while also demonstrating that Indian firms can meet China’s exceptionally tight price ceilings and supply-volume requirements. These footholds suggest potential expansion into other chronic-disease segments—hypertension, dyslipidemia, cardiovascular disease—where China’s VBP framework favors large-scale, cost-competitive suppliers capable of delivering uninterrupted national supply.

However, these gains also highlight the growing competitiveness of China’s own API-integrated manufacturers, as well as the escalating expectations for regulatory quality, supply-chain resilience, and digital-first manufacturing that will define future procurement rounds.

Why India’s Generics Still Win Big—And Why That Edge Is Under Threat

India’s pharmaceutical industry earned its seat at the top of the global generics market through a decade of steady, disciplined operational gains. The country now hosts one of the world’s most extensive high-quality manufacturing ecosystems—752 FDA-approved sites, more than 2,050 WHO-GMP plants, and 286 EDQM facilities. Currently, no other nation matches this density of internationally certified facilities.

Cost competitiveness has also been central to India’s rise. Manufacturing in India remains 30–35% cheaper than in the United States and Europe, supported by a deep base of process engineering talent and decades of scale-building. That edge enabled Indian companies to become essential suppliers of affordable medicines, particularly during the COVID-19 pandemic, when they delivered uninterrupted essential-drug supply while many other markets experienced shortages.

Over time, Indian manufacturers expanded well beyond basic small molecules. Many now produce complex generics, sterile injectables, biologics, and specialty formulations, while significantly improving compliance and right-first-time performance after years of regulatory scrutiny.

These strengths explain why India can compete—and win—in hyper-price-sensitive markets such as China’s VBP program. But they also mask a growing reality: the generics model that built India’s leadership is no longer enough.

China’s VBP Snapshot: Scale, Competition, and Price Pressure

China’s most recent VBP tender illustrates the scale—and intensity—of competition:

• 55 drugs included in the tender round
• 453 product submissions from 272 companies
• 1 billion dapagliflozin tablets awarded to a multi-supplier panel
• RMB 8 billion (USD 1.14B) in nationwide dapagliflozin sales last year
• RMB 5.3 billion purchased by public hospitals alone

Annora Pharma received a contract for oxcarbazepine tablets; Natco Pharma secured olaparib; and Dr. Reddy’s Jiangsu subsidiary won four additional product bids. Executives describe the tenders as both access points to a massive market and operational stress tests: margins are extremely thin, and only firms with highly efficient, zero-failure manufacturing systems can sustain profitability.

A Global Shift: Procurement Systems Are Rewriting the Rules

The pressures observed in China now appear across Asia, Europe, Africa, and Latin America. Governments are redesigning procurement and reimbursement systems to prioritize affordability, regulatory transparency, and uninterrupted supply.

Key observations include:

• Japan continues to lower reimbursement ceilings through its regular national drug price revisions, which apply price cuts to a large share of listed medicines and adjust rates based on real-world utilization. These reductions increasingly target long-listed drugs, biologics, and oncology products, reflecting the country’s long-term cost-containment strategy.
• In Southeast Asia, health ministries are expanding pooled tenders for essential and chronic-disease therapies, enabling countries to consolidate demand, reduce price variation, and strengthen access in lower-income regions. Several ASEAN members have begun coordinating procurement for high-burden conditions such as diabetes, hypertension, and infectious diseases, using regional tender platforms to negotiate lower prices and improve continuity of supply.
• Across Africa, procurement bodies are integrating supply-chain stability metrics into contract scoring. Ministries now evaluate bidders on manufacturing redundancy, API sourcing diversity, and the ability to maintain uninterrupted delivery during logistics disruptions. These criteria aim to reduce dependence on single-country suppliers and ensure resilience against geopolitical shocks, transportation bottlenecks, and raw-material shortages.

Together, these reforms demand unprecedented levels of cost discipline, quality consistency, and operational predictability.

A New Global Reality: The Old Rules for Generics No Longer Apply

Across much of the world, health systems are redesigning procurement systems in ways that fundamentally change the generics business. Countries in Asia, Europe, Africa, and Latin America now prioritize affordability, supply security, and advanced manufacturing reliability—not simply low price.

Several shifts stand out:

Ultra-low pricing tied to population-scale tenders: China’s VBP framework, Japan’s cost-containment policies, and Southeast Asia’s expanding pooled tenders reward manufacturers that can deliver huge volumes at historically low prices. The floor keeps falling, and only the most efficient producers can survive long-term.

Zero-defect manufacturing as a baseline requirement:Regulators now expect AI-driven deviation detection, digital batch records, and real-time monitoring capable of approaching eight-sigma performance. Plants that rely on manual documentation or periodic inspections are increasingly disqualified.

Supply chains that can survive shocks: Governments want to avoid single-country API dependence. They are pushing manufacturers to establish distributed production networks, local final-fill capabilities, and redundant sourcing.

Capability in complex, high-value therapies: Demand is shifting toward biologics, oncology agents, and specialty formulations for diabetes and autoimmune diseases—products that require digital manufacturing, continuous processing, and advanced analytics.

A CDMO mindset, not a commodity mindset: Buyers now prefer suppliers that behave like strategic partners: transparent, flexible, data-rich, and able to adapt output quickly.

India’s strengths open doors, but older manufacturing strategies—large static plants, labor-intensive workflows, incremental efficiency gains—close them just as quickly.

The Inflection Point: Indian Pharma Needs a New S-Curve

Industry analysts now argue that India’s generics engine is approaching a performance plateau. To stay competitive in markets like China’s VBP—and to secure long-term leadership—companies must shift to an entirely new operational model. This shift could span eight potential areas identified across frameworks from ICH, the U.S. FDA, the EMA, WHO, and major public-procurement authorities in the EU, U.K., and China.

1. Zero-error operations: Quality systems must move from reacting to problems to preventing them. Future-ready plants aim for >99.9% right-first-time, <0.01% batch failures, and zero repeat deviations.
2. Autonomous, AI-run plants: Facilities will increasingly rely on automation, digital twins, and self-correcting workflows—reducing manufacturing costs by 40%, driving OEE above 70%, and cutting downtime by 70%.
3. Modular, miniaturized manufacturing: Continuous manufacturing, micro-reactors, and “plant-in-plant” setups allow for smaller, more flexible—and more resilient—operations, especially for biologics and high-potency APIs.
4. CDMO-style customer experience: Buyers expect real-time quality dashboards, transparent deviation pathways, and output adjusted to national needs. Suppliers must operate like service organizations, not commodity producers.
5. Deep cost leadership that extends to large molecules: To stay competitive, firms need de novo API-route optimization, last-person-standing strategies for mature molecules, and procurement analytics that eliminate raw-material waste.
6. Distributed global manufacturing networks: Regulators increasingly prefer suppliers with multi-region production nodes and dedicated centers of excellence capable of handling complex regulatory portfolios.
7. Fully autonomous supply-chain planning: AI-enabled planning can lower supply-chain costs by 30%, raise service levels above 98%, and shorten lead times by 25–40%.
8. Net-zero-aligned operations as a qualification criterion: Sustainability now influences tender scoring. Companies must address Scope 3 emissions, redesign packaging, and adopt solvent-recycling and process-efficiency measures that reduce both cost and carbon.

These eight shifts reflect a single reality: modernization is no longer optional. Global buyers are writing these requirements directly into their procurement frameworks.

Why China’s VBP Wins Matter for India

India’s wins in China confirm that its generics industry still ranks among the world’s most competitive in scale, reliability, and cost. But those same wins reveal the direction of global policy:

• Price ceilings will keep tightening.
• Chinese API-integrated manufacturers will intensify competitive pressure.
• More countries will adopt VBP-style tender models.
• Continuous manufacturing and AI-driven quality will become standard expectations.

Indian companies can continue winning—but only if they accelerate modernization and move beyond legacy models. The next decade will reward manufacturers that operate autonomous, data-intensive, geographically diversified, and environmentally aligned supply networks capable of producing high-volume, high-complexity medicines with near-zero failure.

India has built the foundation. The question now is whether its generics industry can build the next S-curve before global procurement systems leave the old model behind.

Related posts:

Taiwan’s Semiconductor Industry Steers Global Tech Amidst Economic Headwinds and Regionalization Strategic Outsourcing: How CDMO Partnerships Are Tipping the Scales from Cost Efficiency to Supply Chain Resilience BMS to Sell 60% Stake in China JV SASS, Marking a Four-Decade Turning Point Sanae Takaichi Makes History — Can Japan’s First Female PM Turn Symbolism Into Strategy?

Author

Bernice Lottering